Harrison School of Pharmacy
Faculty and Staff Directory
Unit: Drug Discovery and Development
Harrison School of Pharmacy
347 Pharmacy Research Building
Auburn, AL 36849
- B.Pharm., Pharmaceutical Sciences - Zhejiang University (China), 2002
- M.Sc., Biology - National University of Singapore, 2006
- Ph.D., Pharmaceutics - Tennessee, 2011
Feng Li, Ph.D. is an Assistant Professor in the Department of Drug Discovery and Development in the Harrison School of Pharmacy. He joined HSOP on July 1, 2017. He received his B.Pharm. in Pharmaceutical Science from Zhejiang University in China in 2002, M.Sc. in Biology from the National University of Singapore in 2006, and Ph.D. in Pharmaceutics from the University of Tennessee in 2011.
Prior to joining HSOP, Dr. Li served as an Assistant in the Department of Pharmaceutical Sciences at Hampton University from 2011-17. While working on his doctorate, Li was a research assistant from 2006-11 in the Department of Pharmaceutical Sciences at the University of Tennessee. From 2004-06, while pursuing his master's degree, he was a research assistant in the Institute of Bioengineering and Nanotechnology at the National University of Singapore.
- Drug Delivery & Nanomedicine
- Self-assembled Nanosystems ( e.g., Metal-organic Nanostructure, metal-drug complex)
- Pharmacometrics & Computational Pharmaceutics
Dr. Li has been focused on the development of novel drug formulations and delivery systems for the treatment and diagnosis of cancers, dental diseases, and others. Some ongoing research projects are described as follows:
- One project is focused on developing nanomedicine for treating resistant prostate cancers. Although chemotherapy has been successfully used to treat prostate cancers, a large population of patients develops resistance to chemotherapy. Thus, there is an urgent need for effective therapies to treat resistant cancers. The ultimate goal of this research is to develop safe and effective nanomedicines to treat resistant cancers, which involves the design of effective therapeutic agents and appropriate delivery systems. Dr. Li used three major strategies in designing therapeutic agents including (1) use of combination therapy, (2) discovery of novel anticancer agents, (3) repurpose of “old” approved drugs. We developed customized nanoparticle delivery system for specific drug(s). These delivery systems will overcome drug delivery challenges and enhance drug delivery into tumors.
- Dr. Li also devoted himself to the delivery and targeting of macromolecule therapeutics including gene medicine and proteins for treating various diseases. Because of their unique physicochemical properties (large molecule weight, highly hydrophilic, poor stability), the delivery of these therapeutic agents is a significant challenge for their clinical applications. In the past, he has used various delivery strategies to enhance their delivery into target cells and effectively treat different diseases.
- Another research interest is to develop drug formulations and biomaterials for treating dental diseases including pediatric caries and periodontitis.